drugset / Trial / NCT02470741

Pilot of Letrozole for Uterine Myomas

NCT02470741

Phase 4 Completed 12 enrolled University of California, San Francisco
RandomizedParallel-groupDouble-blindTreatment

Summary

PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with symptomatic uterine fibroids. Participants will be randomly assigned in a 1:1 ratio to either oral letrozole 2.5mg/day for 6 months (Group A) or intermittent dosing with letrozole 2.5mg/day and an identical placebo capsule (Group B).

Timeline

Start
2015-07
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral

Indications